The U.S. home infusion therapy market size is expected to reach USD 17.8 billion by 2026, registering a CAGR of 4.9% during the forecast period, according to a new report by Grand View Research, Inc. Rising geriatric population and prevalence of health conditions such as cancer, immune deficiencies, Crohn's disease, infections, dehydration, nutritional deficiencies, multiple sclerosis, and gastrointestinal diseases is driving the demand for home infusion therapy in the country.
Growing cases of Hospital Acquired Infections (HAI) is another major driver for the U.S. market for home infusion therapy. According to the US Center for Disease Control and Prevention (CDC), annually, approximate 1.7 million admitted patients are affected by Health Care-associated infections (HCAI) and around 98,000 patients-one in every 17 patients- die due to HCAIs. This factor is anticipated to substantially drive the demand for home infusion therapy.
Increasing innovations in home infusion therapy such as, incorporation of electronic healthcare records (EHR) along with medical devices and infusion pumps are expected to further fuel the market in the forthcoming years. The EHRs allow storage, retrieval, and alteration of medical records, making it easier for healthcare professionals and patients to track improvements in the particular health condition.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/us-home-infusion-therapy-market
Increasing preference for home healthcare owing to its cost-efficiency over hospital stay is expected to create an opportunity for the industry players to launch more innovative products. Also, the introduction of safety products will ultimately help the growth of the U.S. home infusion therapy market.
U.S. Home Infusion Therapy Market Report Highlights
· Infusion pumps segment held the largest market share in 2018, due to increasing use and efficiency in delivering required quantities of nutrition, medications, and other essential fluids
· Needleless connectors is anticipated to lead the product segment with the fastest CAGR over the forecast period owing to various benefits, such as reduced risk of bacterial contamination and higher protection against needlestick injuries
· Anti-infective application segment held the maximum share of the U.S. home infusion therapy market in 2018 owing to extensive use as antifungal, antibiotics, and antiviral agents at home care
· Endocrinology application is projected to register the fastest CAGR over the forecast period, owing to growing number of conditions associated with endocrine system, such as thyroid and diabetes
· Some of the key market players include B. Braun Melsungen; Baxter International; Caesarea Medical Electronics Ltd.; CareFusion; Fresenius Kabi; ICU Medical; JMS CO., LTD.; Smiths Medical, Inc.; Terumo Corporation; Coram LLC; Option Care Enterprises, Inc.; BioScrip, Inc.; BriovaRx Infusion Services; and Paragon Healthcare